# US 2023/0338479 A1 · High-activity blood coagulation factor xi mutant ala570thr

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0338479 A1
- Document ID: US20230338479A1
- Status: Published application
- Kind: A1
- Application number: 18/025,398
- Filed: 2021-04-13
- Published: 2023-10-26
- Earliest claimed: 2020-09-09
- Assignees: Wenman WU; Xuefeng WANG; Qiulan DING; Ruijin Hospital Shanghai Jiaotong University School of Medicine
- Applicants: Ruijin Hospital Shanghai Jiaotong University School of Medicine
- Inventors: Wenman WU; Xuefeng WANG; Qiulan DING
- Web page: https://patentgrep.com/patent/US20230338479A1

## CPC

- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 38/40: Transferrins, e.g. lactoferrins, ovotransferrins
- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07K 14/745: Blood coagulation or fibrinolysis factors
- C12N 9/6443: {Coagulation factor XIa (3.4.21.27)}
- C12Y 304/21027: Coagulation factor XIa (3.4.21.27)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A high-activity blood coagulation factor XI mutant Ala570Thr (A570T), having nucleotide sequences as shown in SEQ ID NOs: 1-4 and an amino acid sequence as shown in SEQ ID NO: 5, is provided. The mutant is resistant to a physiological inhibitor thereof after being activated from a zymogen state to an active enzyme. Therefore, the mutant has a very high blood coagulation activity and a stronger catalytic ability for a non-physiological substrate; and the mutant is applied to the treatment of hemorrhagic diseases, and has good prospects in terms of gene therapy, gene editing and recombinant protein replacement treatments.

## Claims

### Claim 1

A high-activity blood coagulation factor XI mutant Ala570Thr, having:
(1) a nucleotide sequence as shown in SEQ ID NO: 1; or
(2) a nucleotide sequence as shown in SEQ ID NO: 2; or
(3) a nucleotide sequence as shown in SEQ ID NO: 3; or
(4) a nucleotide sequence as shown in SEQ ID NO: 4; or
a combination of mutations of any other nucleotide at positions 1708, 1709 and 1710.

### Claim 2 (depends on 1)

A mutein of the high-activity blood coagulation factor XI mutant Ala570Thr according to claim 1, wherein an amino acid sequence is as shown in SEQ ID NO: 5, and an amino acid, located at position 570 of the mutant is Thr rather than Ala of non-human wild-type FXI; or any other amino acid mutates at the position.

### Claim 3 (depends on 2)

A nucleic acid encoding the mutein according to claim 2, or a nucleic acid having the same length as the coding nucleic acid and being completely complementary to the coding nucleic acid.

### Claim 4 (depends on 2)

A vector expressing the mutein according to claim 2.

### Claim 5 (depends on 1)

A method for preparing a mutein of a high-activity blood coagulation factor XI mutant Ala570Thr, comprising the following steps:
(1) ligating a gene encoding the high-activity blood coagulation factor XI mutant Ala570Thr according to claim 1 into a vector to obtain a recombinant vector;
(2) transforming the recombinant vector described above into a host cell to obtain clones of mutant cells expressing a recombinant blood coagulation factor XI Ala570Thr;
(3) performing continuous perfusion culture on the recombinant cell clones in a serum-free medium to induce expression of the mutein of the recombinant blood coagulation factor XI Ala570Thr; and
(4) separating, purifying, filtering, finally filling, and freeze-drying to obtain the expressed high-activity blood coagulation factor XI Ala570Thr mutein.

### Claim 6 (depends on 1)

An application of a mutein of a high-activity blood coagulation factor XI mutant Ala570Thr and a coding nucleic acid sequence thereof, wherein the nucleotide sequence according to claim 1 is applied to prepare a gene therapy drug, comprising ligating the nucleotide sequence to a sequence of a promoter and/or a terminator, constructing an expression plasmid, and a viral or non-viral vector for gene therapy, and expressing the mutein of the high-activity blood coagulation factor XI mutant.

### Claim 7 (depends on 2)

An application of the mutein of the high-activity blood coagulation factor XI mutant Ala570Thr according to claim 2 and a coding nucleic acid sequence thereof, comprising applying to a viral or non-viral vector or template for gene editing.

### Claim 8 (depends on 2)

An application of the mutein of the high-activity blood coagulation factor XI mutant Ala570Thr according to claim 2, comprising applying to preparation of recombinant protein therapeutic drugs for hemophilia or other hemorrhagic diseases.

### Claim 9 (depends on 2)

An application of the mutein of the high-activity blood coagulation factor XI mutant Ala570Thr according to claim 2, comprising applying to preparation of a fusion protein of the blood coagulation factor XI Ala570Thr mutant, which is applied to recombinant protein therapeutic drugs for hemophilia or other hemorrhagic diseases.

### Claim 10 (depends on 9)

The application according to claim 9, wherein the fusion protein is human albumin, immunoglobulin Fc, transferrin or alpha 1 antitrypsin.

### Claim 11 (depends on 3)

An application of a mutein of a high-activity blood coagulation factor XI mutant Ala570Thr and a coding nucleic acid sequence thereof, wherein the nucleotide sequence according to claim 3 is applied to prepare a gene therapy drug, comprising ligating the nucleotide sequence to a sequence of a promoter and/or a terminator, constructing an expression plasmid, and a viral or non-viral vector for gene therapy, and expressing the mutein of the high-activity blood coagulation factor XI mutant.

### Claim 12 (depends on 3)

An application of the mutein of the high-activity blood coagulation factor XI mutant Ala570Thr according to claim 3 and a coding nucleic acid sequence thereof, comprising applying to a viral or non-viral vector or template for gene editing.
